NVIDIA and Eli Lilly unveiled a five-year, $1 billion co-innovation AI lab in the San Francisco Bay Area, built on NVIDIA's BioNeMo platform, aiming to accelerate drug discovery, clinical development, and manufacturing.
Aidoc's CARE foundation model won FDA clearance to flag 14 acute conditions from a single abdominal CT scan, a consolidation the company says cuts false alerts roughly tenfold versus running separate single-purpose AI tools.
The NHS-linked GEMINI study found AI-assisted mammography screening increased breast cancer detection by 10.4% while cutting radiologist reading time by up to a third, intensifying pressure on other countries' screening programs.
The FDA cleared Neosoma's Brain Mets software on December 17, 2025, an AI tool that detects, measures, and contours an unlimited number of brain metastases from standard MRI scans for radiation therapy planning.
Takeda signed a collaboration worth up to $600 million with Insilico Medicine on July 3, 2026, tapping the company's generative AI drug-discovery platform to find new molecules—part of a $7 billion deal-making sprint that has investors excited and skeptics waiting for actual approvals.
Recursion Pharmaceuticals says REC-4881, a drug its AI platform found through unbiased cell-imaging screens rather than a predetermined target, cut polyp burden by more than half in patients with familial adenomatous polyposis, a disease with no approved drug treatment.
George Mason University's Injury Analytics Lab has patented an AI system that adjusts imaging to skin tone and combines it with electronic health record data to detect and assess bruises more consistently, aiming to close a long-documented equity gap in injury detection.
Twelve major US health systems, together caring for nearly 20 million patients a year, have joined Aidoc to form a Diagnostic AI Consortium aimed at building shared standards for how diagnostic AI is evaluated and governed across hospitals.
Samsung and Massachusetts General Hospital's Diabetes Research Center are testing whether Galaxy Watch8 sensors and AI-guided coaching can help patients on GLP-1 drugs preserve muscle mass, validating wearable data against clinical DXA scans.
An NIH-funded study used deep learning to analyze thrice-daily smartphone surveys from 62 patients in opioid addiction treatment, accurately forecasting relapse risk hours to days in advance, though researchers caution the small, non-diverse sample needs broader validation.